Previous Article | Next Article 
Infection and Immunity, August 1999, p. 4027-4032, Vol. 67, No. 8
0019-9567/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
A Murine Model for Infection with
Burkholderia cepacia with Sustained Persistence in the
Spleen
David P.
Speert,1,2,3,*
Barbara
Steen,2
Keith
Halsey,1 and
Eddie
Kwan1
Division of Infectious and Immunological
Diseases, Department of Pediatrics,1
Department of Microbiology and
Immunology,2 and the Centre for
Microbial Diseases and Host Defence Research,3
University of British Columbia, Vancouver, British Columbia, Canada
V5Z 4H4
Received 28 January 1999/Returned for modification 15 April
1999/Accepted 10 May 1999
 |
ABSTRACT |
Burkholderia cepacia is an opportunistic pathogen that
causes severe systemic infections in patients with chronic
granulomatous disease (CGD) or with cystic fibrosis (CF), but its
mechanisms of virulence are poorly understood. We developed a murine
model of systemic infection in wild-type (WT) and gamma interferon
knockout (GKO) BALB/c mice to facilitate dissection of components of
pathogenicity and host defense. Both WT and GKO mice were susceptible
to chronic splenic infection with B. cepacia, but not with
Pseudomonas aeruginosa. B. cepacia strains from patients
with CGD persisted longer than those from CF patients. C57BL/6 mice
were the most susceptible murine strain; bacteria persisted in the
spleen for 2 months. DBA/2, BALB/c, and A/J strains of mice were
relatively resistant to infection. Certain strains of B. cepacia complex can persist in the murine spleen after systemic
infection; this may provide clues to its virulence in compromised
hosts, such as those with CGD and CF.
 |
INTRODUCTION |
Burkholderia cepacia was
originally isolated in 1952 as the cause of sour skin rot in onions
(1), and since that time has become recognized as an
important pathogen in certain compromised hosts. Whereas it is one of
the recognized pathogens in patients with cystic fibrosis (CF) (6,
11) or with chronic granulomatous disease (CGD) (23),
a unifying explanation for its predilection for these two dissimilar
diseases remains elusive. A clearer understanding of the pathogenicity
of this evolving pathogen would be greatly aided by a suitable
animal model of infection.
B. cepacia is an extremely diverse class of bacteria, and in
fact, is probably comprised of at least five discrete species (27). The term "genomovar" is used to describe the five
potential novospecies within the B. cepacia complex
(27). New species designations have recently been proposed
for those genomovars which have characteristic phenotypes; genomovar II
has been designated Burkholderia multivorans, and genomovar
V is Burkholderia vietnamiensis. Most strains of B. cepacia from patients with CF are in genomovar III, and this
genomovar contains all strains in the epidemic ET/12 cable
pilus-possessing lineage and most of the strains which carry the
B. cepacia epidemic strain marker (13a, 14).
Patients with CGD are at risk of infection with certain classes of
bacteria and fungi which are able to evade the limbs of phagocytic
defense which operate independent of an intact NADPH oxidase system
required for production of oxidative radicals. These patients are
susceptible to infection with B. cepacia, but not another
common gram-negative opportunistic pathogen (Pseudomonas aeruginosa), because the former but not the latter can resist the
nonoxidative bactericidal activity of polymorphonuclear leukocytes, upon which CGD neutrophils are dependent for killing (23).
Furthermore, B. cepacia is responsible for particularly
devastating infections in some patients with CF. Certain of these
patients succumb to "cepacia syndrome," which is characterized by
necrotizing pneumonia and septicemia (11). This type of
infection is notably different from P. aeruginosa infections
in CF, which are characteristically slowly progressive and noninvasive.
An explanation for the striking differences between the infections of
these two organisms in CF remains elusive.
To date, one of the most effective prophylactic strategies for patients
with CGD is human recombinant gamma interferon (IFN-
) (10). IFN-
is an important cytokine produced by natural
killer cells and T helper cells. It exerts a number of regulatory
effects during the course of infection and is an important positive
regulator for the T helper cell type 1 (Th1) immune response and
inhibits the Th2 response (12). Perhaps the principal role
of IFN-
in host defense against infection is its capacity to
activate macrophages with subsequent production of reactive oxidative
radicals, which are toxic to phagocytosed organisms (17).
Nonetheless, phagocytic cells from patients with CGD, treated with
IFN-
, do not appear to have an enhanced ability to generate reactive
oxygen radicals (10). The mechanism by which IFN-
decreases the rate of serious infections in patients with CGD is
currently not understood.
In order to begin to explore the virulence determinants of
B. cepacia and the normal host defenses against this
evolving human pathogen, we established a murine model of systemic
infection. This model has facilitated the investigation of
the relative virulence of different strains of B. cepacia and P. aeruginosa, as well as
providing insight into the role of IFN-
in host defense. These studies yielded data suggesting that B. cepacia (but
not P. aeruginosa) is able to persist for up to 2 months in
the murine spleen, that there are substantial differences in virulence
among strains of B. cepacia, and that IFN-
knockout (GKO)
mice were not substantially compromised in their capacity to defend
themselves against systemic challenge.
 |
MATERIALS AND METHODS |
Bacterial strains and media.
The bacterial strains used in
this study and their characteristics are listed in Table
1. They were stored at
70°C in
Mueller-Hinton broth with 8.0% dimethyl sulfoxide. All strains were
cultured on blood agar plates (PML Microbiologicals, Richmond, British Columbia, Canada), and all colony counts were performed on tryptic soy
agar (TSA) plates (Becton Dickinson, Cockeysville, Md.).
Serum sensitivity testing.
A fresh overnight culture of
bacteria grown in Luria-Bertani broth at 37°C was centrifuged and
resuspended in Hank's balanced salt solution with 0.1% (wt/vol)
gelatin (gHBSS [Gibco BRL, Grand Island, N.Y.]) and adjusted to a
concentration of 8 × 108 bacteria per ml. Bacteria
were cultured at 105 per ml in the presence of 10%
(vol/vol) pooled human serum at 37°C in gHBSS. Samples were taken at
zero, 2, and 3 h, diluted serially in gHBSS, and quantitated by
plating on TSA and incubation at 37°C for up to 72 h. Serum
sensitivity was assessed on the following scale: resistant if there was
no loss in viability after 3 h; resistant/sensitive if there was
no change in log CFU at 2 h, but 1 log10 drop in CFU
after 3 h; and sensitive if there was 1 log10 drop in
CFU observed after 2 h.
Mice.
These studies were approved by the University of
British Columbia Animal Care Committee (A96-0373). Mating pairs of
heterozygote BALB/c GKO mice were kindly provided by Genentech, Inc.
(San Francisco, Calif.). The mice were bred for the homozygous
recessive GKO and homozygous normal dominant wild-type (WT) progeny.
The construction of these mouse strains is the same as the original
description of GKO mice (5). C57BL/6, DBA/2, and BALB/c mice
were purchased from Charles River, St. Constant, Canada, and A/J mice
were purchased from Jackson Laboratories, Bar Harbor, Maine. All mice
were housed and cared for in accordance with regulations of the
University of British Columbia Animal Care Committee and The Canadian
Council on Animal Care. Mice weighed between 20 and 25 g and were
6 to 8 weeks old at the commencement of each experiment.
PCR genotyping of mice.
Progeny from the original
heterozygote mating pairs were screened for the GKO and WT genotypes by
PCR amplification primed for the normal IFN-
gene
(5'-AGAAGTAAGTGGAAGGGCCCAGAAG-3' and 5'-AGGGAAACTGGGAGAGGAGAAATAT-3') and the disrupted gene
(5'-TCAGCGCAGGGGCGCCCGGTTCTTT-3' and
5'-ATCGACAAGACCGGCTTCCATCCGA-3'). Oligonucleotides were
synthesized by the Nucleic Acids-Protein Service Unit at the University
of British Columbia. Approximately 3.0 mm of mouse ear was snipped from
each animal postmortem. These were incubated in 20 µg of proteinase K
per ml (Boehringer Mannheim, GmbH, Mannheim, Germany) with 1.0%
(wt/vol) sodium dodecyl sulfate and 50 mM Tris-Cl. Zirconial silica
beads (0.5 ml [0.5-mm diameter]) (Biospec Products, Inc., Bartlesville, Okla.) were added, and the tubes were placed in a bead
beater for 1 min (Fisher, Nepean, Canada). The beads were removed by
microcentrifugation. Potassium acetate (3.0 M) was added at 0.1 volumes
to the supernatant, followed by phenol-chloroform extraction and
precipitation by ethanol. DNA was resuspended in Tris-EDTA buffer (10 mM Tris-HCl, 1.0 mM EDTA [pH 8.0]) and stored at 4°C. DNA was
amplified in the presence of the specific primers (Perkin-Elmer DNA
Thermocycler). The amplified DNA was separated by electrophoresis on a
1.5% agarose gel and stained with ethidium bromide.
Infection of mice.
Bacteria were cultured from frozen stocks
for 24 to 48 h on blood agar plates at 37°C. Several isolated
colonies were picked and grown in 5.0 ml of LB broth for 16 h and
harvested by centrifugation (10 min at 3,000 × g) and
then resuspended in gHBSS. Bacteria were adjusted to approximately
8 × 108 CFU/ml with a Beckman Du 640 spectrophotometer. Bacteria were then diluted in gHBSS to 8 × 106 CFU/ml for B. cepacia and 7 × 105 CFU/ml for P. aeruginosa. Mice were
challenged intraperitoneally with 0.5 ml of either B. cepacia or P. aeruginosa through a 25G needle. At
preselected times after infection, groups of four mice were
anesthetized with sodium pentobarbital and killed by cervical dislocation. During the necropsy, the gall bladder was excised, as were
the spleen, liver, and lungs, by sterile technique. Three samples from
liver, lung, and spleen were preserved for histology by freezing in
liquid nitrogen by fixation in 10% buffered Formalin (Starplex
Scientific) and in 3% buffered glutaraldehyde (Canemco, Inc.). The
remaining tissues were then weighed, diluted 10-fold in gHBSS, and
homogenized for up to 30 s in sterile 10-ml glass tubes with a
sterilized Teflon pestel (Glas-col, Terre Haute, Ind.). During the
necropsy, an examination for any lesion or abscess was performed. The
homogenates and serial dilutions of the homogenates were plated on TSA,
and viable bacterial counts were enumerated after 24, 48, and 72 h
of incubation at 37°C.
Histology.
Formalin-fixed tissues were processed in a Fisher
Histomatic 266 tissue processor and embedded in paraffin wax blocks.
The tissues were cut into 2-µm sections, stained with Gram's stain and hematoxylin and eosin stain, and inspected for pathological changes
and the presence of bacteria.
Statistical methods.
Data were analyzed by using SPSS for
Windows version 7.5 software. For each experiment, assumptions for
normal distribution were violated, since data for CFU per gram of
tissue were skewed. Therefore, the nonparametric tests by Wilcoxon and
Kruskal-Wallis were used for comparing groups. Wilcoxon's test was
used for comparison of two groups, and the Kruskal-Wallis test was used
for comparisons of more than two groups. For each experiment, the
overall type 1 error was held at 0.05 by use of Bonferroni's
correction. Plots were generated with Sigma Plot version 3.0 software
(Jandel Scientific).
 |
RESULTS |
Genotyping of mice.
As shown in Fig.
1, the PCR amplification using primers
specific for the intact IFN-
gene gave a product 220 bp in size, and
the primers specific for the neomycin cassette in the GKO mutation
resulted in a product 375 bp in size. WT BALB/c mice gave a single
220-bp band, mice homozygous for the mutation in the IFN-
gene gave
a single 375-bp band, and mice with both bands were heterozygous for
the mutation. The genotype for each mouse was confirmed by PCR after
each experiment.

View larger version (40K):
[in this window]
[in a new window]
|
FIG. 1.
PCR products of the murine IFN- gene. Lanes: 1 and 2, heterozygotic mice; 3 and 4, WT mice; 5 and 6, GKO mice. See Materials
and Methods for details. The unnumbered leftmost lane contains
molecular size markers.
|
|
Intraperitoneal infection of WT and GKO mice with P. aeruginosa or B. cepacia.
Figure
2 shows the results of experiments in
which we determined the relative susceptibility of WT versus GKO mice
to infection with bacterial species which were either susceptible
(P. aeruginosa) or resistant (B. cepacia) to
nonoxidative neutrophil-mediated killing. P. aeruginosa M2
is traditionally used for mouse pathogenicity studies (25),
and B. cepacia JTC was from a fatal infection in a patient
with CGD (23). Pilot experiments demonstrated that P. aeruginosa was cleared more rapidly from WT mice than was B. cepacia, so different time courses were evaluated for the two different pathogens.

View larger version (28K):
[in this window]
[in a new window]
|
FIG. 2.
Intraperitoneal infection of BALB/c WT ( ) and GKO
( ) mice with P. aeruginosa M2 (A) or B. cepacia JTC (B). Mice were infected with ~3 × 105 CFU of P. aeruginosa and then sacrificed at
0, 1, 2, 4, and 7 days or with ~4 × 106 CFU of
B. cepacia and sacrificed at 0, 2, 7, 14, 21, 28, and 35 days. Quantitative bacteriology of the spleen, liver, and lung was
assessed at each time point. Data are the mean and standard error of
the mean from 12 animals at each time point. An asterisk indicates a
significant difference (P < 0.05) between WT and GKO
mice at that time point.
|
|
P. aeruginosa, at a challenge dose of ~3 × 10
5 CFU, administered intraperitoneally, was cleared from
both the WT and GKO mice
by 7 days with only modest differences between
the two (Fig.
2A).
At higher infectious challenges (5 × 10
5), there was substantial mortality (data not shown). At
the sublethal
dose chosen, there were no gross or microscopic
pathological changes
in any of the three
organs.
The results with
B. cepacia were strikingly different (Fig.
2B). A dose of 4 × 10
6 CFU was used for all
experiments and resulted in bacteria being
recovered from the spleen
consistently after intraperitoneal challenge.
The results were
similar after intravenous challenge (data not
shown), so the
intraperitoneal route was used for simplicity and
high reproducibility.
Unlike
P. aeruginosa,
B. cepacia could be
recovered from BALB/c mice for at least 35 days after systemic
challenge. Whereas the bacteria were rapidly cleared from the
lung and
liver, they were recovered at approximately 10
4 CFU/g of
spleen for the first 4 weeks of infection. Unexpectedly,
the GKO mice
cleared this strain of
B. cepacia more rapidly from
the
spleen than did the WT mice, suggesting that IFN-

was not
critically
important in defense against this opportunistic
pathogen.
To determine if the observations of relative susceptibility to these
two pathogens could be extended to other strains in these
two species
of bacteria, we evaluated six other strains of
P. aeruginosa
in WT BALB/c mice (Fig.
3A) and three in
GKO mice (Fig.
3B). The sources and serum susceptibilities (in human
serum) are
given in Table
1. Serum-resistant versus serum-susceptible
strains
were tested to identify any possible correlation with
virulence.
The same infecting dose was used for the strains in these
experiments
as was used with strain M2, and in all cases, the bacteria
were
cleared from spleen, liver, and lung by day 7. There was no
consistent
difference between serum-resistant and serum-sensitive
strains;
however, the one strain which was still recoverable after 4 days
(C4020) was serum resistant. As with strain M2, there was no
substantial
difference between the WT and GKO mice in their capacity to
clear
these strains of
P. aeruginosa.

View larger version (26K):
[in this window]
[in a new window]
|
FIG. 3.
Intraperitoneal infection of wild-type BALB/c mice with
~3 × 105 CFU of six different strains of P. aeruginosa (A) or GKO BALB/c mice with three different strains of
P. aeruginosa (B). Quantitative bacteriology of the spleen,
liver, and lung was assessed at 0, 1, 4, and 7 days. Data are the mean
and standard error of the mean from four animals at each time point.
, C4020; , P1; , C0489; , C0262; , C0295; , C0487.
|
|
Six additional strains of
B. cepacia were evaluated in WT
(Fig.
4A) and GKO (Fig.
4B) BALB/c mice.
Strains were from patients
with CGD or CF and were from genomovar V or
III (Table
1). All
six strains were cleared from the WT animals by day
35, and at
day 14, only two strains (C2303 and FC441) were present, at
approximately
10
4 CFU/g of spleen. FC441, the only
genomovar V strain tested, was
cleared poorly by GKO mice. It was
recovered at high number from
spleen, liver, and lung at 35 days, and
at necropsy, an intraperitoneal
abscess and splenomegaly were found.
This strain was recovered
from a prolonged septicemic illness in a
patient with X-linked
recessive CGD (unpublished observation). The
pattern of illness
in this patient was atypical, because he was
persistently bacteremic,
in contrast to most patients with CGD, whose
blood cultures are
consistently negative in the face of severe invasive
infection
(unpublished data).

View larger version (34K):
[in this window]
[in a new window]
|
FIG. 4.
Intraperitoneal infection of wild-type BALB/c mice with
~4 × 106 CFU of six different strains of B. cepacia (A) and GKO BALB/c mice with six different strains of
B. cepacia (B). Quantitative bacteriology of the spleen,
liver, and lung was assessed at 0, 2, 14, and 35 days. Data are the
mean and standard error of the mean from four animals at each time
point. An asterisk indicates a significant difference (P < 0.05) among strains at the indicated time point in the spleen
only. , C2303; , C1257; , C5424; , C2389; , C5491; ,
FC441.
|
|
Susceptibility of different murine strains to infection with
B. cepacia.
Notable differences in susceptibility to
intracellular and extracellular bacterial infection have been
observed among inbred strains of mice. In order to begin to understand
the host determinants of protection against B. cepacia,
we evaluated two murine strains which have been shown to differ
in their susceptibilities to infection with P. aeruginosa
(16). Figure 5 shows the
results of an experiment in which BALB/c and C57BL/6 mice were
challenged with B. cepacia JTC. As observed in previous
experiments, the bacteria were rapidly cleared from liver and lung, but
could be cultured from the spleen for 35 days. C57BL/6 mice appeared to
be more susceptible to infection; B. cepacia could be
recovered from the spleen for 56 days (Fig. 5). These observations were
extended to infection with a total of three strains of B. cepacia (from genomovars II, III, and V) and four strains of mice
(Fig. 6). All strains of B. cepacia were cleared rapidly from liver and lung (Fig. 6B and 6C).
In Fig. 6A (spleen), A/J and DBA/2 mice appeared to be more resistant to B. cepacia infection (similar to BALB/c mice). C57BL/6
mice were the most susceptible strain tested in this study. However, this observation appears to be unique to B. cepacia JTC
(genomovar II), which persisted the longest in murine strain C57BL/6,
with 105 CFU/g of spleen recovered at 35 days and
approximately 102 CFU/g recovered after 56 days. Although
the latter number is too small to be considered quantitatively
reliable, it demonstrates the extraordinary capacity of this species of
bacteria to persist in the spleen after systemic infection. Bacterial
strains FC441 and C2303 showed no significant difference in resistance
or susceptibility for any of the mouse strains tested.

View larger version (19K):
[in this window]
[in a new window]
|
FIG. 5.
Intraperitoneal infection of wild-type BALB/c ( ) or
C57BL/6 ( ) mice with B. cepacia JTC. Quantitative
bacteriology of the spleen, liver, and lung was assessed at 0, 2, 7, 14, 21, 28, 35, 56, 77, and 98 days. Data are the mean and standard
error of the mean from four animals at each time point.
|
|

View larger version (24K):
[in this window]
[in a new window]
|
FIG. 6.
Intraperitoneal infection of wild-type A/J ( ),
C57BL/6 ( ), BALB/c ( ), or DBA/2 ( ) mice with B. cepacia JTC, FC441, and C2303. Quantitative bacteriology of the
spleen (A), liver (B), and lung (C) was assessed at 0, 7, 35, and 56 days. Data are the mean and standard error of the mean from four
animals at each time point.
|
|
Histological evaluation of murine infection with B. cepacia.
No consistent histological abnormalities were seen in
liver, lung, or spleen from mice infected with any of the bacterial strains. Specimens from 27 animals, with high or low bacterial counts,
were examined. Liver, spleen, and lung were available from 26 of these
animals, and liver and lung only were available from 1 animal.
 |
DISCUSSION |
B. cepacia is an important evolving pathogen in
patients with CF or with CGD, but its mechanisms of pathogenesis are
very poorly understood. The purpose of these studies was to develop an
animal model of infection which would permit a systematic investigation of potential virulence determinants and host defense mechanisms. We
chose to pursue our investigations with a systemic challenge model
because B. cepacia infections in these two dissimilar
disease states are characteristically invasive, as opposed to the
mucosal respiratory tract disease characteristic of P. aeruginosa infections in patients with CF. Indeed, one of the
strains of B. cepacia (FC441) was recovered from a
15-year-old boy with X-linked CGD at British Columbia's Children's
Hospital, who suffered a prolonged bout of septicemia with multiple
organ infection from which he recovered after a long course of
aggressive antimicrobial therapy (unpublished data). B. cepacia is also a particularly virulent pathogen in patients with
CF, with a characteristic syndrome of necrotizing pneumonia,
septicemia, and death (11). Furthermore, patients with CF
who are colonized with B. cepacia and undergo lung
transplantation are at very high risk of dying postoperatively from
B. cepacia septicemia (22).
IFN-
therapy is very effective at preventing serious infections
(including those with B. cepacia) in patients with CGD, but its mechanism of action is poorly understood. One of the goals of this
study was to try to determine a role for IFN-
in defense against
this bacterium. We chose to utilize a GKO model, hypothesizing that
these mice would be compromised in their capacity to clear B. cepacia. We were surprised to observe that the GKO mice were no worse at clearing B. cepacia than were their WT isogenic
littermates. The mouse model was designed by using B. cepacia JTC. We found that the GKO mice were able to clear this
strain of B. cepacia more efficiently than the WT BALB/c
mice. Whereas a clear role for IFN-
in defense against infection
with intracellular pathogens has been demonstrated by other
investigators (12), the same may not be the case for
B. cepacia. IFN-
is an important immune modulator early
in infection. It regulates the proliferation and function of activated
T lymphocytes. It acts as a promoter of Th1 response and down-regulates
the Th2 cellular immune response (29). Thus, a role for Th1
cells in host defense against B. cepacia or P. aeruginosa infection cannot be inferred from these data. In the
GKO mouse, a more profound activation of the Th2 response may be
occurring in the absence of inhibition by IFN-
, suggesting that
resistance in the GKO mice to B. cepacia JTC may correlate
with a Th2-dominated immune response. A formal evaluation of Th1 versus
Th2 cells in host defense against infection with either P. aeruginosa or B. cepacia was beyond the scope of these studies.
It has been suggested by other investigators that B. cepacia
may be an intracellular pathogen. This conclusion is drawn from several
observations, including its propensity to cause chronic infections and
its capacity to enter and replicate within respiratory epithelial cells
(6). Our data support the possibility of intracellular pathogenicity. We observed that the bacteria could persist for up to 2 months in the murine spleen and that in so doing, an insubstantial inflammatory response was induced. This murine model provides an ideal
opportunity to investigate the nature of the persistent infection. We
are currently attempting to determine the cell(s) in which it persists
by infecting mice with green fluorescent-tagged bacteria and then
evaluating splenic tissues en bloc with fluorescent microscopy or after
single-cellular dispersion followed by fluorescence-activated cell sorting.
This model may also permit the identification of microbial virulence
determinants. We evaluated a range of bacterial strains in order to
attempt to draw conclusions about two fairly broad and diverse
bacterial species. The strains of P. aeruginosa were recovered from mouse intestine (25) or from the respiratory tract of patients with CF. Recent observations have suggested that
there is a difference in the capacity of different strains of P. aeruginosa to invade epithelial cells (2, 8), and these
differences may be due, in part, to products exported by a type III
secretion apparatus (28). Our data do not support a
difference among these strains in their capacity to cause serious murine infection; at the dose studied, ~3 × 105
CFU, all animals (both WT and GKO) cleared the bacteria completely by 7 days. However, our model differs from those reported by the other
investigative groups (8, 28); we were interested in infection rather than invasion as an endpoint.
The model was designed by using strain JTC, which was isolated from a
CGD patient and belongs to genomovar II. Strain JTC showed persistence
in the spleen for up to 56 days in the WT C57BL/6 mice (Fig. 6A) and
for 20 days in the GKO mice (Fig. 2B). This suggested that IFN-
does
not play an essential role in host defense against this strain. Strain
C2303 was the only one of five CF isolates from genomovar III
(including cable pilus-positive strain C5424) that persisted past 14 days, and no significant difference was seen between the WT and GKO
BALB/c mice in clearance of any CF strains. The second CGD isolate
tested in this model, FC441, is a member of genomovar V. This strain
was eliminated from the spleen of WT BALB/c mice, but persisted in the
spleen, liver, and lung of GKO mice (Fig. 4B), suggesting that IFN-
may play a role in the immune response against this strain of B. cepacia. These data suggest that strains of B. cepacia
from different genomovars may have substantially different pathogenic
potentials in mice and that this range of pathogenicities may correlate
with human disease severity. Evaluation of many more strains will be
required before any firm conclusions about virulence can be drawn.
Potential virulence determinants, as opposed to colonizing factors,
have not yet been identified, but their characterization may be greatly facilitated by use of this animal model.
A number of bacterial determinants have been identified which may play
a role in virulence of B. cepacia. These include
lipopolysaccharide (9), pili (13, 19, 26),
protease (15), hemolysin, phospholipase C, siderophores, and
exopolysaccharide (6, 18). Although each of these has been
shown to facilitate a potential step in pathogenesis in vitro, none has
been shown to enhance disease per se. One characteristic of B. cepacia which appears to enhance its virulence is resistance to
nonoxidative phagocytic killing (23) and to cationic
peptides (24). This is likely a result of an unusual
lipopolysaccharide which is relatively impermeable due to a low number
of phosphate residues (4). We have recently engineered a
mutant of B. cepacia which is susceptible to cationic peptides and which appears to have a disruption of one of the genes
involved in LPS biosynthesis (24). The animal model
described in this paper should be well suited to evaluate the relative
virulence of strains of B. cepacia with mutations leading to
alterations in production of these different potential virulence
determinants. We are also attempting to identify novel virulence
determinants by using transconjugation and signature-tagged mutagenesis
(7).
Clues to defense against microbial challenge have been gained from the
study of different inbred strains of mice (12). For instance, specific strains are susceptible or resistant to infection with Mycobacterium bovis bacillus Calmette-Guerin and are
designated bcgr or bcgs
(21). The bcg gene has been identified in the
mouse (20), and a human homologue has recently been cloned
and codes for a protein named the "human natural
resistance-associated macrophage protein" (3). A similar
approach may be possible in determining the gene(s) involved in
resistance or susceptibility to infection with different B. cepacia strains by comparing susceptible (C57BL/6) to resistant
(DBA/2, BALB/c, and A/J) mice. Such studies are planned and may shed
new light on strategies used by this pathogen to persist and/or cause
devastating infection in certain compromised hosts.
In summary, we have developed a new animal model of invasive infection
with B. cepacia. This model should aid in the dissection of
microbial determinants of infectivity as well has determinants of host
defense. Such studies may aid in the design of novel anti-infective strategies for this highly adapted opportunistic pathogen.
 |
ACKNOWLEDGMENTS |
This work was supported with funds from Genentech, Inc., the
British Columbia Lung Association, and the Canadian Cystic Fibrosis Foundation. Barbara Steen was supported by a studentship from the
Canadian Cystic Fibrosis Foundation.
We thank Laurie Ainsworth for statistical analysis, Fergall Magee for
histological evaluation, Karen Chu and Jacqueline Chung for technical
assistance, and Eshwar Mahenthiralingam and Richard Stokes for advice.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: BC Research
Institute for Children's & Women's Health, Room 377, 950 West 28th
Ave., Vancouver, B.C., Canada V5Z 4H4. Phone: (604) 875-2438. Fax:
(604) 875-2226. E-mail: speert{at}unixg.ubc.ca.
Editor:
E. I. Tuomanen
 |
REFERENCES |
| 1.
|
Burkholder, W. H.
1952.
Sour skin, a bacterial rot of onion bulbs.
Phytopathology
40:115-117.
|
| 2.
|
Burns, J. L.,
M. Jonas,
E. Y. Chi,
D. A. Clark,
A. Berger, and A. Griffith.
1996.
Invasion of respiratory epithelial cells by Burkholderia (Pseudomonas) cepacia.
Infect. Immun.
64:4054-4059[Abstract].
|
| 3.
|
Cellier, M.,
G. Govoni,
S. Vidal,
T. Kwan,
N. Groulx,
J. Liu,
F. Sanchez,
E. Skamene,
E. Schurr, and P. Gros.
1994.
Human natural resistance-associated macrophage protein: cDNA cloning, chromosomal mapping, genomic organization, and tissue-specific expression.
J. Exp. Med.
180:1741-1752[Abstract/Free Full Text].
|
| 4.
|
Cox, A. D., and S. G. Wilkinson.
1991.
Ionizing groups in lipopolysaccharides of Pseudomonas cepacia in relation to antibiotic resistance.
Mol. Microbiol.
5:641-646[Medline].
|
| 5.
|
Dalton, D. K.,
S. Pitts-Meek,
S. Keshav,
I. S. Figari,
A. Bradley, and T. A. Stewart.
1993.
Multiple defects of immune cell function in mice with disrupted interferon-gamma genes.
Science
259:1739-1745[Abstract/Free Full Text].
|
| 6.
|
Govan, J. R. W., and V. Deretic.
1996.
Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia.
Microbiol. Rev.
60:539-574[Abstract/Free Full Text].
|
| 7.
|
Hensel, M.,
J. E. Shea,
C. Gleeson,
M. D. Jones, and D. W. Holden.
1995.
Simultaneous identification of bacterial virulence genes by negative selection.
Science
269:400-403[Abstract/Free Full Text].
|
| 8.
|
Hirakata, Y.,
K. Izumikawa,
T. Yamaguchi,
S. Igimi,
N. Furuya,
S. Maesaki,
K. Tomono,
Y. Yamada,
S. Kohno,
K. Yamaguchi, and S. Kamihira.
1998.
Adherence to and penetration of human intestinal Caco-2 epithelial cell monolayers by Pseudomonas aeruginosa.
Infect. Immun.
66:1748-1751[Abstract/Free Full Text].
|
| 9.
|
Hughes, J. E.,
J. Stewart,
G. R. Barclay, and J. R. W. Govan.
1997.
Priming of neutrophil respiratory burst activity by lipopolysaccharide from Burkholderia cepacia.
Infect. Immun.
65:4281-4287[Abstract].
|
| 10.
|
The International Chronic Granulomatous Disease Cooperative Study Group.
1991.
A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease.
N. Engl. J. Med.
324:509-516[Abstract].
|
| 11.
|
Isles, A.,
I. Maclusky,
M. Corey,
R. Gold,
C. Prober,
P. Fleming, and H. Levison.
1984.
Pseudomonas cepacia infection in cystic fibrosis: an emerging problem.
J. Pediatr.
104:206-210[Medline].
|
| 12.
|
Kaufmann, S. H. E.
1995.
Immunity to intracellular microbial pathogens.
Immunol. Today
16:338-342[Medline].
|
| 13.
|
Krivan, H. C.,
V. Ginsburg, and D. D. Roberts.
1988.
Pseudomonas aeruginosa and Pseudomonas cepacia isolated from cystic fibrosis patients bind specifically to gangliotetraosylceramide (Asialo GM1) and gangliotriaosylceramide (Asialo GM2).
Arch. Biochem. Biophys.
260:493-496[Medline].
|
| 13a.
| Mahenthiralingam, E., et al. Unpublished
observations.
|
| 14.
|
Mahenthiralingam, E.,
D. A. Simpson, and D. P. Speert.
1997.
Identification and characterization of a novel DNA marker associated with epidemic Burkholderia cepacia strains recovered from patients with cystic fibrosis.
J. Clin. Microbiol.
35:808-816[Abstract].
|
| 15.
|
McKevitt, A. I.,
S. Bajaksouzian,
J. D. Klinger, and D. E. Woods.
1989.
Purification and characterization of an extracellular protease from Pseudomonas cepacia.
Infect. Immun.
57:771-778[Abstract/Free Full Text].
|
| 16.
|
Morissette, C.,
E. Skamene, and F. Gervais.
1995.
Endobronchial inflammation following Pseudomonas aeruginosa infection in resistant and susceptible strains of mice.
Infect. Immun.
63:1718-1724[Abstract].
|
| 17.
|
Murray, H. W.
1988.
Interferon-gamma, the activated macrophage, and host defense against microbial challenge.
Ann. Intern. Med.
108:595-608.
|
| 18.
|
Nelson, J. W.,
S. L. Butler,
D. Krieg, and J. R. W. Govan.
1994.
Virulence factors of Burkholderia cepacia.
FEMS Immunol. Med. Microbiol.
8:89-98[Medline].
|
| 19.
|
Sajjan, S. U., and J. F. Forstner.
1992.
Identification of the mucin-binding adhesin of Pseudomonas cepacia isolated from patients with cystic fibrosis.
Infect. Immun.
60:1434-1440[Abstract/Free Full Text].
|
| 20.
|
Schurr, E.,
E. Skamene,
A. Forget, and P. Gros.
1989.
Linkage analysis of the Bcg gene on mouse chromosome 1: identification of a tightly linked marker.
J. Immunol.
142:4507-4513[Abstract].
|
| 21.
|
Skamene, E.,
P. Gros,
A. Forget,
P. A. L. Kongshavn,
C. St. Charles, and B. A. Taylor.
1982.
Genetic regulation of resistance to intracellular pathogens.
Nature
297:506-509[Medline].
|
| 22.
|
Snell, G. I.,
A. de Hoyos,
M. Krajden,
T. Winton, and J. R. Maurer.
1993.
Pseudomonas cepacia in lung transplant recipients with cystic fibrosis.
Chest
103:466-471[Abstract/Free Full Text].
|
| 23.
|
Speert, D. P.,
M. Bond,
R. C. Woodman, and J. T. Curnutte.
1994.
Infection with Pseudomonas cepacia in chronic granulomatous disease: role of nonoxidative killing by neutrophils in host defense.
J. Infect. Dis.
170:1524-1531[Medline].
|
| 24.
|
Steen, B. A.,
R. E. W. Hancock, and D. P. Speert.
1998.
Characterization of a Burkholderia cepacia mutant with increased susceptibility to cationic peptides.
Pediatr. Pulmonol.
17(Suppl.):380A.
|
| 25.
|
Stieritz, D. D., and I. A. Holder.
1975.
Experimental studies of the pathogenesis of infections due to Pseudomonas aeruginosa: description of a burned mouse model.
J. Infect. Dis.
131:688-691[Medline].
|
| 26.
|
Sun, L.,
R.-Z. Jiang,
S. Steinbach,
A. Holmes,
C. Campanelli,
J. Forstner,
U. Sajjan,
Y. Tan,
M. Riley, and R. Goldstein.
1995.
The emergence of a highly transmissible lineage of cbl+ Pseudomonas (Burkholderia) cepacia causing CF centre epidemics in North America and Britain.
Nat. Med.
1:661-666[Medline].
|
| 27.
|
Vandamme, P.,
B. Holmes,
M. Vancanneyt,
T. Coenye,
B. Hoste,
R. Coopman,
H. Revets,
S. Lauwers,
M. Gillis,
K. Kersters, and J. R. W. Govan.
1997.
Occurrence of multiple genomovars of Burkholderia cepacia in cystic fibrosis patients and proposal of Burkholderia multivorans sp. nov.
Int. J. Syst. Bacteriol.
47:1188-1200[Abstract/Free Full Text].
|
| 28.
|
Yahr, T. L.,
J. Goranson, and D. W. Frank.
1996.
Exoenzyme S of Pseudomonas aeruginosa is secreted by a type III pathway.
Mol. Microbiol.
22:991-1003[Medline].
|
| 29.
|
Young, H. A., and K. J. Hardy.
1995.
Role of interferon- in immune cell regulation.
J. Leukoc. Biol.
58:373-381[Abstract].
|
Infection and Immunity, August 1999, p. 4027-4032, Vol. 67, No. 8
0019-9567/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Whitby, P. W., VanWagoner, T. M., Taylor, A. A., Seale, T. W., Morton, D. J., LiPuma, J. J., Stull, T. L.
(2006). Identification of an RTX determinant of Burkholderia cenocepacia J2315 by subtractive hybridization. J Med Microbiol
55: 11-21
[Abstract]
[Full Text]
-
Chung, J. W., Altman, E., Beveridge, T. J., Speert, D. P.
(2003). Colonial Morphology of Burkholderia cepacia Complex Genomovar III: Implications in Exopolysaccharide Production, Pilus Expression, and Persistence in the Mouse. Infect. Immun.
71: 904-909
[Abstract]
[Full Text]
-
Chu, K. K., Davidson, D. J., Halsey, T. K., Chung, J. W., Speert, D. P.
(2002). Differential Persistence among Genomovars of the Burkholderia cepacia Complex in a Murine Model of Pulmonary Infection. Infect. Immun.
70: 2715-2720
[Abstract]
[Full Text]
-
Cieri, M. V., Mayer-Hamblett, N., Griffith, A., Burns, J. L.
(2002). Correlation between an In Vitro Invasion Assay and a Murine Model of Burkholderia cepacia Lung Infection. Infect. Immun.
70: 1081-1086
[Abstract]
[Full Text]
-
Sajjan, U., Thanassoulis, G., Cherapanov, V., Lu, A., Sjolin, C., Steer, B., Wu, Y. J., Rotstein, O. D., Kent, G., McKerlie, C., Forstner, J., Downey, G. P.
(2001). Enhanced Susceptibility to Pulmonary Infection with Burkholderia cepacia in Cftr{-}/{-} Mice. Infect. Immun.
69: 5138-5150
[Abstract]
[Full Text]
-
Berriatua, E., Ziluaga, I., Miguel-Virto, C., Uribarren, P., Juste, R., Laevens, S., Vandamme, P., Govan, J. R. W.
(2001). Outbreak of Subclinical Mastitis in a Flock of Dairy Sheep Associated with Burkholderia cepacia Complex Infection. J. Clin. Microbiol.
39: 990-994
[Abstract]
[Full Text]